# Myth Busted: medical cannabis is not the same for every patient. Two patients may have the … > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/myth-busted-medical-cannabis-is-not-the-same-for-every-patient-two-patients-may-have-the/ > **Published:** 2026-08-16T12:23:57-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:56:17-04:00 > **Clinical Summary:** Personalized cannabis prescribing requires individual assessment, not empiric dosing. Learn clinical frameworks for individualization. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchDosingSafetyPainAnxietyMental HealthNeurology Why This Matters Clinicians need to understand that cannabis products vary significantly in cannabinoid profiles and effects, requiring individualized assessment rather than treating all patients identically. This evidence supports moving beyond simplified cannabis recommendations toward standardized dosing protocols and consistent monitoring of patient outcomes. Patients deserve personalized treatment plans that account for their specific conditions, genetics, and concurrent medications rather than one-size-fits-all approaches. Clinical Summary # Clinical Summary Medical cannabis demonstrates significant inter-individual variability in efficacy and tolerability, requiring personalized treatment approaches rather than standardized protocols across all patients. Genetic factors, metabolic differences, concurrent medications, underlying pathophysiology, and cannabinoid chemotype preferences all contribute to differential therapeutic responses, meaning that an effective regimen for one patient may prove ineffective or poorly tolerated in another. This variability underscores the importance of systematic patient assessment, including baseline symptom severity, comorbidities, and prior medication trials, to optimize cannabis selection and dosing. Clinicians should recognize that successful medical [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) requires iterative dose titration and product adjustment based on individual patient response rather than application of uniform treatment protocols. The personalized approach to [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) parallels evidence-based prescribing in other therapeutic areas and reflects the complexity of [cannabinoid pharmacology](https://cedclinic.com/cannabinoid-drug-interactions-clinical-evidence/) and patient heterogeneity. For clinical practice, this means establishing baseline measures, using structured follow-up assessments, and being prepared to adjust or change cannabis formulations when initial responses are suboptimal rather than prematurely concluding that cannabis is ineffective for a given patient. Clinical Perspective 💊 The emerging evidence that medical cannabis effects vary significantly across individual patients underscores an important clinical reality: cannabis cannot be prescribed as a one-size-fits-all intervention, despite its growing availability in many jurisdictions. This heterogeneity in response reflects multiple overlapping factors including genetic differences in [cannabinoid metabolism](https://cedclinic.com/fatty-acid-amide-hydrolase-obesity-risk-genetic-links/), varying [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) function, differences in disease phenotypes, concomitant medications, and prior cannabis exposure—complexities that complicate both research synthesis and clinical decision-making. While the principle of personalized treatment is sound, clinicians should recognize that our current evidence base for individualizing [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) remains limited compared to other medications, and robust biomarkers or validated prediction tools to guide patient selection are still lacking. Additionally, confounding factors such as placebo response, variable product composition and potency, and reporting bias in patient populations can obscure true treatment effects in clinical practice. To advance cannabis as a genuinely person 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Myth%20Busted%3A%20medical%20cannabis%20is%20not%20the%20same%20for%20every%20patient.%20Two%20patients%20may%20have%20the%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73564)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73564)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Myth%20Busted%3A%20medical%20cannabis%20is%20not%20the%20same%20for%20every%20patient.%20Two%20patients%20may%20have%20the%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D73564)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [When Kentucky Medical Cannabis Dispensaries Begin Selling Vapes & Concentrates](https://cedclinic.com/kentucky-medical-cannabis-vapes-dispensaries-launch/) - [Cannabis 101: What Should You Really Know?](https://cedclinic.com/cannabis-101-essential-facts/) 📰 Source: [https://x.com/mamedicauk/status/2088271966163603902](https://x.com/mamedicauk/status/2088271966163603902) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).